• patients
  • Activating mutations in FLT3 have been identified in approximately 30% of patients with acute myelogenous leukemia, making it one of the most common mutations observed in this disease. (jove.com)
  • Only two patients, one with SM-myelofibrosis and one with SM-chronic eosinophilic leukemia, achieved complete response (elimination of mastocytosis) lasting for 5 and 16 months, respectively. (aacrjournals.org)
  • Although standard cytoreductive therapies for SM may provide symptomatic improvements, responses are transient and the overall prognosis, which is particularly poor for patients with ASM, SM-AHNMD, and mast cell leukemia, remains unchanged by treatment ( 4 ). (aacrjournals.org)
  • Despite
  • If your leukemia is not severe enough to equal or meet a listing, the Social Security Administration must assess your residual functional capacity (RFC) (the work you can still do, despite your leukemia), to determine whether you qualify for benefits at Step 4 and Step 5 of the Sequential Evaluation Process. (thesocialsecurityattorney.com)